Yamaha Motor: Consolidated Business Results Summary
8.8.2023 19:00:00 EEST | Business Wire | Press release
Yamaha Motor Co., Ltd. (Tokyo:7272) announces its consolidated business results for the first half of fiscal 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230808613856/en/
Yamaha Motor Headquarters, Iwata, Shizuoka, Japan (Photo: Business Wire)
Net sales for the consolidated accounting period for the first six months of the fiscal year ending December 31, 2023 were 1,226.4 billion yen (an increase of 157.5 billion yen or 14.7% compared with the same period of the previous fiscal year) and operating income was 142.8 billion yen (an increase of 40.3 billion yen or 39.4%). Ordinary income was 144.8 billion yen (an increase of 29.4 billion yen or 25.4%) and net income attributable to owners of parent was 105.3 billion yen (an increase of 22.3 billion yen or 26.9%). This is also the first time net income has exceeded 100 billion yen in a second quarter period.
For the first half-year consolidated accounting period, the U.S. dollar traded at 135 yen (a depreciation of 12 yen from the same period of the previous fiscal year) and the euro at 146 yen (a depreciation of 12 yen).
Market conditions during the second quarter were affected by factors that include subsiding outdoor recreation demand and a protracted economic recovery in China, but demand for large outboard motors and motorcycles remained strong. Compared to last year when the Company faced supply chain disruptions, marked improvements were made with product supply volumes and this resulted in higher sales. For operating income, higher unit sales as well as more pronounced effects from passing on costs to offset soaring prices for raw materials generated higher profits. Together with the positives of a weaker yen, led the Company to post record highs for net sales and incomes for a second quarter consolidated accounting period.
Forecast of Consolidated Business Results (Compared with the previous fiscal year)
Net Sales: 2,500 billion yen
(an increase of 251.5 billion yen or 11.2%)
Operating Income: 250.0 billion yen
(an increase of 25.1 billion yen or 11.2%)
Ordinary Income: 250.0 billion yen
(an increase of 10.7 billion yen or 4.5%)
Net Income Attributable to Owners of Parent: 180.0 billion yen
(an increase of 5.6 billion yen or 3.2%)
*Trading rate during the fiscal year: the U.S. dollar at 135 yen, the euro at 145 yen.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230808613856/en/
Contact information
Ayuko Kobayashi
Corporate Communication Division
Global PR Team
Yamaha Motor Co., Ltd.
TEL: +81(0)538-32-1145
ymc_pr@yamaha-motor.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom